连续血液净化治疗脓毒症合并急性肾损伤的进展

脓毒症（sepsis）是导致重症监护患者死亡的常见原因。脓毒症患者如合并急性肾损伤（AKI），其病死率明显增加。但目前对脓毒症的发生机制尚不明确。近年国内外关于脓毒症治疗的研究证实，连续性肾脏替代治疗（CRRT），又称连续性血液净化（CBP），在脓毒症的治疗中可发挥显著作用，使患者内环境和免疫内稳态机制得到明显改善，遏制了一系列严重病理生理紊乱，提高了危重病患者救治的成功率。本文将对CRRT/CBP在脓毒症合并AKI中的临床疗效和研究进展作一综述。

Progress of continuous blood purification in treatment of sepsis complicated with AKI

Sepsis is the most common cause of death among critically ill patients. The mortality will increase significantly if sepsis patients combine with acute kidney injury. However, the mechanism of sepsis development remains unclear nowadays. Both domestic and international researches on the sepsis management showed that continuous renal replacement therapy (CRRT), also known as continuous blood purification (CBP), plays a significant role in the treatment of sepsis. CRRT can improve the patients′ internal environment and immune homeostasis, inhibit a series of fundamental pathophysiological disorders, and increase the success rate of therapy. We will talk about the clinical efficacy and research progress of CRRT/CBP in patients with sepsis combined with AKI in this review.